CinCor Pharma, Inc
CinCor Pharma, Inc. (NASDAQ: CINC), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, CINC shareholders are expected to receive $26.00 and one Contingent Value Right worth $10.00 in cash per share they own.